US lawmaker moves bill to ban Chinese biotech firms from federal contracts, alleging complicity with military
- Bill cites Chinese entities such as Third Military Medical University and Key Laboratory of High-Altitude Medicine as examples of ‘espionage tools’ of the Communist Party
- The biotech index, which tracks the 50 biggest companies in biotech, pharmaceuticals and medical devices, tumbled 5.4 per cent
A US lawmaker has proposed a bill to block Chinese biotechnology companies doing business with the US government due to alleged complicity with the Chinese military, broadening the ongoing sanctions in sectors including hi-tech, semiconductors and cotton production over economic, political and human rights issues.
China seeks to dominate biotechnology as an industry of the future, and the nation’s biotech firms “have repeatedly collaborated with PLA [the People’s Liberation Army] entities” with power to compel them to turn over their data, according to a bill moved by Republican Mike Gallagher of Wisconsin this week.
The bill cited Third Military Medical University and Key Laboratory of High-Altitude Medicine, entities it said are “an espionage tool” of the Communist Party. Other entities mentioned include BGI, formerly known as Beijing Genomics Institute, and WuXi Apptec, a sister company of WuXi Biologics.
27:21
Biden’s China tech policy goal: a 10 year handicap
“The time has come to stop US taxpayer dollars from flowing to foreign adversary biotech companies like BGI that have ties to the PLA, and prevent taxpayers from buying biotech equipment from foreign adversaries that facilitate the transfer of US persons’ genetic data to a foreign adversary,” according to the bill.
The move represents an escalation in Washington’s technology ban on Chinese companies. The biotech industry had remained largely unscathed, until the latest provocation. It is further evidence that Washington’s “small yard and high fence” strategy is getting tighter, not easier, despite a summit involving presidents Xi Jinping and Joe Biden in California last November.
01:56
Biden to introduce new restrictions on US investments in China, declares tech ‘emergency’
WuXi Biologics sank 18 per cent to HK$24.55, the biggest drop since December 4, to erase HK$23.2 billion (US$3 billion) from its market value. WuXi Apptec, which only became a Hang Seng Index member last month, plunged 16 per cent to HK$64.60.
